Pierre Popczyk, Alina Ghinet, Clovis Bortolus, Laure Kamus, Marc F Lensink, Jérôme de Ruyck, Boualem Sendid, Faustine Dubar
{"title":"Antifungal and anti-biofilm effects of hydrazone derivatives on <i>Candida</i> spp.","authors":"Pierre Popczyk, Alina Ghinet, Clovis Bortolus, Laure Kamus, Marc F Lensink, Jérôme de Ruyck, Boualem Sendid, Faustine Dubar","doi":"10.1080/14756366.2024.2429109","DOIUrl":"10.1080/14756366.2024.2429109","url":null,"abstract":"<p><p>Worldwide, invasive candidiasis are a burden for the health system due to difficulties to manage patients, to the increasing of the resistance of the current therapeutics and the emergence of naturally resistant species of <i>Candida</i>. In this context, the development of innovative antifungal drugs is urgently needed. During invasive candidiasis, yeast is submitted to many stresses (oxidative, thermic, osmotic) in the human host. In order to resist in this context, yeast develops different strategy, especially the biosynthesis of trehalose. Starting from the 3D structural data of TPS2, an enzyme implicated in trehalose biosynthesis, we identified hydrazone as an interesting scaffold to design new antifungal drugs. Interestingly, our hydrazone derivatives which demonstrate antifungal and anti-biofilm effects on <i>Candida spp</i>., are non-toxic in <i>in vitro</i> and <i>in vivo</i> models (<i>Galleria mellonella</i>).</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2429109"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad Abdel-Halim, Dalia S El-Gamil, Mennatallah A Hammam, Mohamed El-Shazly, Yi-Hsuan Wang, Po-Hsiung Kung, Yu-Cheng Chen, Michal Korinek, Ashraf H Abadi, Matthias Engel, Tsong-Long Hwang
{"title":"Discovery of 1,3-disubstituted prop-2-en-1-one derivatives as inhibitors of neutrophilic inflammation via modulation of MAPK and Akt pathways.","authors":"Mohammad Abdel-Halim, Dalia S El-Gamil, Mennatallah A Hammam, Mohamed El-Shazly, Yi-Hsuan Wang, Po-Hsiung Kung, Yu-Cheng Chen, Michal Korinek, Ashraf H Abadi, Matthias Engel, Tsong-Long Hwang","doi":"10.1080/14756366.2024.2402988","DOIUrl":"10.1080/14756366.2024.2402988","url":null,"abstract":"<p><p>Targeting neutrophil function has gained attention as a propitious therapeutic strategy for diverse inflammatory diseases. Accordingly, a series of enone-based derivatives were developed to inhibit neutrophil-mediated inflammation, showing promise for treating inflammatory diseases. These compounds fall into two clusters with distinct effects: one inhibits neutrophilic superoxide (SO) anion production and elastase release triggered by N-formyl-Met-Leu-Phe (fMLF), with compound <b>6a</b> being most effective (IC<sub>50</sub> values of 1.23 and 1.37 μM, respectively), affecting c-Jun N-terminal kinase (JNK) and Akt phosphorylation. The second cluster suppresses formation of SO anion without affecting elastase levels, surpassed by compound <b>26a</b> (IC<sub>50</sub> of 1.56 μM), which attenuates various mitogen-activated protein kinases (MAPKs) with minimal Akt impact. Notably, none of the tested compounds showed cytotoxicity in human neutrophils, underscoring their potential as therapeutic agents against inflammatory diseases.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2402988"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11413964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142288898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Synthesis and biological evaluation of <i>ortho</i>-phenyl phenylhydroxamic acids containing phenothiazine with improved selectivity for class IIa histone deacetylases.","authors":"Kai-Cheng Hsu, Yun-Yi Huang, Jung-Chun Chu, Yu-Wen Huang, Jing-Lan Hu, Tony Eight Lin, Shih-Chung Yen, Jing-Ru Weng, Wei-Jan Huang","doi":"10.1080/14756366.2024.2406025","DOIUrl":"10.1080/14756366.2024.2406025","url":null,"abstract":"<p><p>Class IIa histone deacetylases (HDACs) have been linked to tumorigenesis in various cancers. Previously, we designed phenylhydroxamic acid <b>LH4f</b> as a potent class IIa HDAC inhibitor. However, it also unselectively inhibited class I and class IIb HDACs. To enhance the compound's selectivity towards class IIa HDACs, the <i>ortho</i>-phenyl group from the selective HDAC7 inhibitor <b>1</b> is incorporated into <i>ortho</i> position of the phenylhydroxamic acid in <b>LH4f</b>. Compared to <b>LH4f</b>, most resulting compounds displayed substantially improved selectivity towards the class IIa HDACs. Notably, compound <b>7 g</b> exhibited the strongest HDAC9 inhibition with an IC<sub>50</sub> value of 40 nM. Molecular modelling further identified the key interactions of compound <b>7 g</b> bound to HDAC9. Compound <b>7 g</b> significantly inhibited several human cancer cells, induced apoptosis, modulated caspase-related proteins as well as p38, and caused DNA damage. These findings suggest the potential of class IIa HDAC inhibitors as lead compounds for the development of cancer therapeutics.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2406025"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Keren Xu, Leyi Ying, Titi Ying, Qihao Wu, Lin Du, Yanlei Yu, Youmin Ying, Bin Wei, Hong Wang, Zhikun Yang
{"title":"Design, synthesis, and biological evaluation of (thio)urea derivatives as potent <i>Escherichia coli β</i>-glucuronidase inhibitors.","authors":"Keren Xu, Leyi Ying, Titi Ying, Qihao Wu, Lin Du, Yanlei Yu, Youmin Ying, Bin Wei, Hong Wang, Zhikun Yang","doi":"10.1080/14756366.2024.2387415","DOIUrl":"10.1080/14756366.2024.2387415","url":null,"abstract":"<p><p>EcGUS has drawn considerable attention for its role as a target in alleviating serious GIAEs. In this study, a series of 72 (thio)urea derivatives were designed, synthesised, and biologically assayed. The bioassay results revealed that <b>E-9</b> (IC<sub>50</sub> = 2.68 μM) exhibited a promising inhibitory effect on EcGUS, surpassing EcGUS inhibitor D-saccharic acid-1,4-lactone (DSL, IC<sub>50</sub> = 45.8 μM). Additionally, the inhibitory kinetic study indicated that <b>E-9</b> (K<sub>i</sub> = 1.64 μM) acted as an uncompetitive inhibitor against EcGUS. The structure-activity relationship revealed that introducing an electron-withdrawing group into the benzene ring at the <i>para</i>-position is beneficial for enhancing inhibitory activity against EcGUS. Furthermore, molecular docking analysis indicated that <b>E-9</b> has a strong affinity to EcGUS by forming interactions with residues Asp 163, Tyr 472, and Glu 504. Overall, these results suggested that <b>E-9</b> could be a potent EcGUS inhibitor, providing valuable insights and guidelines for the development of future inhibitors targeting EcGUS.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2387415"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11328603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tingting Wu, Hu Cheng, Lijie Sima, Zhongyuan Wang, Weiwei Ouyang, Jianta Wang, Yunlei Hou, Dongsheng Zhao, Weike Liao, Chujiao Hu
{"title":"Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and <i>in vitro</i> characterisation.","authors":"Tingting Wu, Hu Cheng, Lijie Sima, Zhongyuan Wang, Weiwei Ouyang, Jianta Wang, Yunlei Hou, Dongsheng Zhao, Weike Liao, Chujiao Hu","doi":"10.1080/14756366.2024.2353711","DOIUrl":"10.1080/14756366.2024.2353711","url":null,"abstract":"<p><p>The PD-1/PD-L1 pathway is considered as one of the most promising immune checkpoints in tumour immunotherapy. However, researchers are faced with the inherent limitations of antibodies, driving them to pursue PD-L1 small molecule inhibitors. Virtual screening followed by experimental validation is a proven approach to discover active compounds. In this study, we employed multistage virtual screening methods to screen multiple compound databases to predict new PD-1/PD-L1 ligands. 35 compounds were proposed by combined analysis of fitness scores, interaction pattern and MM-GBSA binding affinities. Enzymatic assay confirmed that 10 out of 35 ligands were potential PD-L1 inhibitors, with inhibitory rate higher than 50% at the concentration of 30 µM. Among them, <b>ZDS20</b> was identified as the most effective inhibitor with low micromolar activity (IC<sub>50</sub> = 3.27 μM). Altogether, <b>ZDS20</b> carrying novel scaffold was identified and could serve as a lead for the development of new classes of PD-L1 inhibitors.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2353711"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia, Timoteo Delgado-Maldonado, Lenci K Vázquez-Jiménez, Gabriel López-Velázquez, José Ignacio de la Mora-de la Mora, Sebastian Pacheco-Gutierrez, Laura Chino-Ríos, Diego Arias, Adriana Moreno-Rodríguez, Alma Paz-González, Eyra Ortíz-Pérez, Gildardo Rivera
{"title":"Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-<i>N</i>-oxide derivatives against <i>Giardia lamblia</i>, <i>Trichomonas vaginalis</i>, and <i>Entamoeba histolytica.</i> An <i>in vitro</i> and <i>in silico</i> approach.","authors":"Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia, Timoteo Delgado-Maldonado, Lenci K Vázquez-Jiménez, Gabriel López-Velázquez, José Ignacio de la Mora-de la Mora, Sebastian Pacheco-Gutierrez, Laura Chino-Ríos, Diego Arias, Adriana Moreno-Rodríguez, Alma Paz-González, Eyra Ortíz-Pérez, Gildardo Rivera","doi":"10.1080/14756366.2024.2413018","DOIUrl":"10.1080/14756366.2024.2413018","url":null,"abstract":"<p><p>In this study, n-butyl and iso-butyl quinoxaline-7-carboxylate-1,4-di-<i>N</i>-oxide derivatives were evaluated <i>in vitro</i> against <i>Giardia lamblia</i> (<i>G. lamblia</i>)<i>, Trichomonas vaginalis</i> (<i>T. vaginalis</i>), and <i>Entamoeba histolytica</i> (<i>E. histolytica</i>). The potential mechanism of action determination was approached by <i>in silico</i> analysis on <i>G. lamblia</i> and <i>T. vaginalis</i> triosephosphate isomerase (<i>Gl</i>TIM and <i>Tv</i>TIM, respectively), and on <i>E. histolytica</i> thioredoxin reductase (<i>EhTrxR</i>). Enzyme inactivation assays were performed on recombinant G<i>l</i>TIM and <i>Eh</i>TrxR. Compound T-167 showed the best giardicidal activity (IC<sub>50</sub> = 25.53 nM) and the highest inactivation efficiency against G<i>l</i>TIM without significantly perturbing its human homolog. Compounds T-142 and T-143 showed the best amoebicidal (IC<sub>50</sub> = 9.20 nM) and trichomonacidal (IC<sub>50</sub> = 45.20 nM) activity, respectively. Additionally, T-143 had a high activity as giardicial (IC<sub>50</sub> = 29.13 nM) and amoebicidal (IC<sub>50</sub> = 15.14 nM), proposing it as a broad-spectrum antiparasitic agent. Compounds T-145, and T-161 were the best <i>Eh</i>TrxR inhibitors with IC<sub>50</sub> of 16 µM, and 18 µM, respectively.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2413018"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines inhibit tubulin polymerisation and act as anticancer agents.","authors":"Chao Wang, Yujing Zhang, Shanbo Yang, Lingyu Shi, Yutao Xiu, Yudong Wu, Hongfei Jiang","doi":"10.1080/14756366.2023.2286939","DOIUrl":"https://doi.org/10.1080/14756366.2023.2286939","url":null,"abstract":"<p><p>A series of <i>cis-</i>restricted 3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines as novel tubulin polymerisation inhibitors was designed based on molecular docking. Compound <b>9p</b>, exhibited potent antiproliferative activity against HeLa, MCF-7, and A549 cell lines. Mechanism studies indicated that <b>9p</b> potently inhibited tubulin polymerisation and disrupted the microtubule dynamics of tubulin in HeLa cells. Moreover, <b>9p</b> could cause G2/M phase cell cycle arrest and apoptosis in HeLa cells. In addition, the prediction of physicochemical properties disclosed that <b>9p</b> conformed well to the Lipinski's rule of five. The initial results suggest that the 3-aryl-4-(3,4,5-trimethoxyphenyl)pyridines could serve as a promising scaffold for the development of novel anticancer drugs.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2286939"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138804867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anti-cancer activity and cellular uptake of 7,3',4'- and 7,8,4'-trihydroxyisoflavone in HepG2 cells under hypoxic conditions.","authors":"Wen-Sheng Tzeng, Wei-Lin Teng, Pao-Hsien Huang, Feng-Lin Yen, Yow-Ling Shiue","doi":"10.1080/14756366.2023.2288806","DOIUrl":"10.1080/14756366.2023.2288806","url":null,"abstract":"<p><p>Transarterial chemoembolisation (TACE) is used for unresectable hepatocellular carcinoma (HCC) treatment, but TACE-induced hypoxia leads to poor prognosis. The anti-cancer effects of soybean isoflavones daidzein derivatives 7,3',4'-trihydroxyisoflavone (734THIF) and 7,8,4'-trihydroxyisoflavone (784THIF) were evaluated under hypoxic microenvironments. Molecular docking of these isomers with cyclooxygenase-2 (COX-2) and vascular endothelial growth factor receptor 2 (VEGFR2) was assessed. About 40 μM of 734THIF and 784THIF have the best effect on inhibiting the proliferation of HepG2 cells under hypoxic conditions. At a concentration of 40 μM, 784THIF significantly inhibits COX-2 expression in pre-hypoxia conditions compared to 734THIF, with an inhibition rate of 67.73%. Additionally, 40 μM 784THIF downregulates the expression of hypoxic, inflammatory, and metastatic-related proteins, regulates oxidative stress, and inhibits the expression of anti-apoptotic proteins. The uptake by HepG2 confirmed higher 784THIF level and slower degradation characteristics under post- or pre-hypoxic conditions. In conclusion, our results showed that 784THIF had better anti-cancer effects and cellular uptake than 734THIF.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2288806"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139048863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xing Jin, Yuting Wang, Jing Chen, Miaomiao Niu, Yang Yang, Qiaoxuan Zhang, Guangyu Bao
{"title":"Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and <i>in vitro</i> and <i>in vivo</i> biological activity evaluations.","authors":"Xing Jin, Yuting Wang, Jing Chen, Miaomiao Niu, Yang Yang, Qiaoxuan Zhang, Guangyu Bao","doi":"10.1080/14756366.2023.2289355","DOIUrl":"10.1080/14756366.2023.2289355","url":null,"abstract":"<p><p>Liver cancer exhibits a high degree of heterogeneity and involves intricate mechanisms. Recent research has revealed the significant role of histone lysine methylation and acetylation in the epigenetic regulation of liver cancer development. In this study, five inhibitors capable of targeting both histone lysine methyltransferase nuclear receptor-binding SET domain 2 (NSD2) and histone deacetylase 2 (HDAC2) were identified using a structure-based virtual screening approach. Notably, DT-NH-1 displayed a potent inhibition of NSD2 (IC<sub>50</sub> = 0.08 ± 0.03 μM) and HDAC2 (IC<sub>50</sub> = 5.24 ± 0.87 nM). DT-NH-1 also demonstrated a strong anti-proliferative activity against various liver cancer cell lines, particularly HepG2 cells, and exhibited a high level of biological safety. In an experimental xenograft model involving HepG2 cells, DT-NH-1 showed a significant reduction in tumour growth. Consequently, these findings indicate that DT-NH-1 will be a promising lead compound for the treatment of liver cancer with epigenetic dual-target inhibitors.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2289355"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of novel ALOX15 inhibitors combining dual machine learning filtering and fragment substitution optimisation approaches, molecular docking and dynamic simulation methods.","authors":"Yinglin Liao, Peng Cao, Lianxiang Luo","doi":"10.1080/14756366.2024.2301756","DOIUrl":"10.1080/14756366.2024.2301756","url":null,"abstract":"<p><p>The oxidation of unsaturated lipids, facilitated by the enzyme Arachidonic acid 15-lipoxygenase (ALOX15), is an essential element in the development of ferroptosis. This study combined a dual-score exclusion strategy with high-throughput virtual screening, naive Bayesian and recursive partitioning machine learning models, the already established ALOX15 inhibitor i472, and a docking-based fragment substitution optimisation approach to identify potential ALOX15 inhibitors, ultimately leading to the discovery of three FDA-approved drugs that demonstrate optimal inhibitory potential against ALOX15. Through fragment substitution-based optimisation, seven new inhibitor structures have been developed. To evaluate their practicality, ADMET predictions and molecular dynamics simulations were performed. In conclusion, the compounds found in this study provide a novel approach to combat conditions related to ferroptosis-related injury by inhibiting ALOX15.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"39 1","pages":"2301756"},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}